PHASE-II STUDY - TREATMENT OF NON-HODGKINS-LYMPHOMA WITH AN ORAL ANTITUMOR DERIVATIVE OF BIS(2,6-DIOXOPIPERAZINE)

Background: Although razoxane (ICRF-159), a derivative of bis(2,6-dioxopiperazine), has shown significant antitumor activity in several murine tumors, inadequate bioavailability has limited its clinical efficacy. Sobuzoxane (MST-16), another derivative of bis(2,6-dioxopiperazine), has shown activity...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 1992-03, Vol.84 (6), p.435-438
Hauptverfasser:	OHNO, R, YAMADA, K, HIRANO, M, SHIRAKAWA, S, TANAKA, M, OGURI, T, KODERA, Y, MITOMO, Y, IKEDA, Y, YOKOMAKU, S, KAMIYA, O, KOBAYASHI, M, SAITO, H, KIMURA, K
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adolescent Adult Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy Drug Evaluation Female Humans Life Sciences & Biomedicine Lymphoma, Non-Hodgkin - drug therapy Male Medical sciences Middle Aged Oncology Pharmacology. Drug treatments Piperazines - adverse effects Piperazines - therapeutic use Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!